Blue under-eye filler: Tyndall effect or a warning sign?
A persistent bluish tint after superficial hyaluronic-acid filler can be an optical Tyndall effect. During or shortly after injection, unusual pain, vision change, white/gray/blue skin near the site, or stroke signs each warrant immediate attention.
A lingering blue-gray cast after under-eye hyaluronic-acid filler can be a Tyndall effect: light interacting with filler placed superficially beneath thin skin. During or shortly after injection, unusual pain, a vision change, white/gray/blue skin near the site, or stroke signs each warrant immediate medical attention under FDA guidance; none requires the others. Timing, the exact finding, product and injection record shape the subsequent clinical evaluation.123
Photographs often flatten this distinction. A cool-colored shadow can come from anatomy, vessels, pigment, lighting or an optical effect; a picture alone cannot establish which. A practice should take a history and examine the area rather than diagnose a complication from a filtered image.
Use timing and each warning sign, not color alone
| Observation | Why it matters | Next responsible step |
|---|---|---|
| Persistent blue-gray cast after swelling settles | May fit an optical Tyndall effect, but pigment and anatomy can look similar | Arrange assessment with the treating clinician and bring product/lot records |
| New white, gray, or blue skin near the site during or soon after injection, even without pain | FDA lists this as a possible vascular warning sign on its own | Seek immediate medical attention |
| Unusual pain, vision change, or stroke signs during or shortly after injection | Each is a separate FDA warning sign | Seek immediate medical attention; do not wait for routine follow-up |
| Delayed lump, redness, tenderness or recurrent swelling | A different process may be involved | Ask a qualified clinician to identify the cause before any corrective plan |
This table is a recognition and handoff aid, not a home diagnostic rule. FDA’s urgent language concerns the during-or-shortly-after pattern and lists alternative findings, not a required symptom cluster. Painless new acute discoloration near the site still warrants immediate attention; an established Tyndall effect is an optical description, not proof that no other problem is present.3
What the product record can establish
Some FDA-approved hyaluronic-acid fillers have product-specific infraorbital-hollow indications. Their labels and patient materials discuss visible color changes, including bluish discoloration, in that precise setting. A label for one under-eye product does not approve every filler for the same location, and a general “FDA-approved HA filler” claim does not reveal injection depth or technique.12
Ask for the brand, formulation, lot, treatment date, site, amount and any prior filler in the area. Those fields help a new clinician distinguish a recent treatment from older material and avoid guessing from appearance. The under-eye approval guide explains how to match the marketed claim to the exact FDA application.
The Tyndall effect is associated with how light encounters superficially placed material. That explanation does not establish the cause of every blue under-eye area, and it does not tell a reader whether a correction is appropriate. A clinician may discuss observation or a product-specific corrective approach after examining the area; Treomark does not provide a dissolving or injection protocol.
Separate the original goal from the current problem
Under-eye hollowing, pigment, vascular show-through, edema and lower-lid bags can coexist. Filler may address one contour issue while leaving another visible. If blue color was present before treatment, a post-treatment image needs a comparable baseline to support a new Tyndall claim. If the complaint is puffiness rather than color, the evaluation may follow a different path.
Bring photos in similar lighting, dates of each procedure, and any new symptoms. Ask the provider to state the leading explanations, what examination would distinguish them, and who owns follow-up. A corrected label of “Tyndall” should not be the endpoint if the person still does not understand the finding or the plan.
At a filler consultation, the useful question is: “Does this pattern fit a delayed optical effect, or is there a finding that requires a different assessment or urgent care?” That one question preserves the distinction FDA makes and makes the next step more reliable than a blanket online reassurance.
Sources
- U.S. Food and Drug Administration. BELOTERO BALANCE (+) patient labeling. Product-specific patient labeling discusses bluish discoloration/Tyndall effect in the infraorbital-hollow context. Accessed .
- U.S. Food and Drug Administration. Restylane Eyelight clinical labeling. Exact under-eye product labeling identifies relevant treatment-site observations and risks. Accessed .
- U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). FDA lists unusual pain, vision change, white/gray/blue skin near the injection site, or stroke signs as alternative urgent findings during or shortly after filler injection. Accessed .